CAR-T Cell Therapy Development for Leukemia

Despite significant advancements in leukemia treatment, the challenge of relapsed or refractory leukemia persists. The introduction of chimeric antigen receptor (CAR) T cell therapy has opened new avenues for treatment. Alfa Cytology offers comprehensive CAR-T cell therapy development services specifically tailored to leukemia treatment.

Introduction to CAR-T Cell Therapy

CAR-T cell therapy is an innovative and promising approach to the treatment of leukemia. CAR stands for CAR, which is a synthetic receptor engineered to be expressed on the surface of T cells. This receptor combines the antigen recognition domain of an antibody with T cell signaling domains, enabling T cells to specifically recognize and target cancer cells. CAR-T cell therapy has achieved remarkable success in acute lymphoblastic leukemia. However, compared with ALL, the application of CAR-T therapy is limited in other types of leukemia.

Fig. 1. The process of autologous CAR-T cell therapy. (Todorovic, Z. et al., 2022)

Our Services

Our expertise extends beyond chronic lymphocytic leukemia, encompassing the exploration of CAR-T cell therapy applications in various other types of leukemia. Through our services, we aim to provide valuable insights and innovative approaches to address the unmet needs in leukemia treatment.

CAR Design and Construction

We specialize in designing CARs that target leukemia cells expressing CD19, CD20, and CD22 antigens, tailored to our clients' needs. Using our advanced platform and extensive database, we generate optimized scFvs with high affinity. We also provide customized redesign services to meet unique requirements. Our focus is on delivering CAR designs that enhance leukemia treatment by improving targeting capabilities.

Cell Activation and Genetic Modification Services

With our extensive experience and advanced technologies in CAR-T development and implementation, we offer genetic modification techniques for T cells. The genetic modification enhances the functionality of CAR-T cells. Our streamlined workflow enables us to provide a substantial quantity of genetically modified, active CAR-T cells within realistic turnaround times.

CAR-T Cell Preparation

Our CAR-T cell preparation service focuses on transferring the genetic material of the CAR construct into T cells using an expression system. Our transduction technologies encompass a wide range of options, including but not limited to adenovirus, lentivirus, retrovirus, synthetic mRNA, and transposons. By leveraging these advanced techniques, we ensure efficient and reliable generation of CAR-T-cells tailored for leukemia treatment.

CAR-T Characterization

Through the utilization of flow cytometry, we can accurately detect CAR expression in the generated CAR-T-cells, facilitating precise quantification of CAR-T cell numbers and evaluation of transduction efficiency. Moreover, our services include vector copy number analysis and immunophenotyping, which enhance your project's overall reliability. We leverage these advanced techniques to ensure a comprehensive and dependable evaluation of CAR-T cell characteristics.

Assessment of CAR-T cell Function

Our service portfolio includes cytokine release assays and cytotoxicity assays to evaluate the efficacy of CAR-T products. In cytokine release assays, we analyze the secretion of important cytokines such as IL-2, IFN-y, TNF-a, and IFN-γ by CAR-T-cells in the supernatant using ELISA. This analysis provides valuable insights into the functional activation of CAR-T-cells.
We offer a comprehensive range of services including the provision of leukemia animal models, biodistribution studies, efficacy testing, toxicology assessments, and trials to evaluate the performance of CAR-T products. We utilize our specialized leukemia animal models to conduct translational analysis, focusing on evaluating the on-target efficacy and off-target killing in CAR-T cell therapy testing.

Advantages of Our Services

We offer a range of bioassays to thoroughly verify CAR-T cell function, ensuring the effectiveness of your treatment.
With our team's professional knowledge and extensive experience in leukemia treatments, we provide expert support throughout your research.
Our comprehensive antibody optimization platform enables us to fine-tune antibodies, optimizing their efficacy and specificity for leukemia treatment.
We understand that every situation is unique, which is why we offer a variety of tailored solutions to meet the diverse needs of our clients.

Alfa Cytology offers a wide range of flexible solutions specifically designed for CAR-T therapy in hematological malignancies. Our comprehensive services cover the entire spectrum, including antibody discovery, novel CAR design, and preclinical research, facilitating advancements in early discovery programs for both combination and novel CAR-T therapies. Please contact us if you would like more information customized to your needs.

Reference

Todorovic, Z.; et al. CAR-T cell therapy for chronic lymphocytic leukemia: successes and shortcomings. Current Oncology. 2022. 29(5): 3647-3657.

For research use only. Not intended for any clinical use.